Categories: Judgements

Decontrolling prices of cardiac, diabetes drugs challenged in SC

New Delhi, October 11, 2014 – Centre’s decision to decontrol prices of 108 cardiac and diabetes drugs was today challenged before theSupreme Court which agreed to hear the case “as soon as possible”.

The PIL alleged that hike in prices of life saving drugs is against the public interest and would lead to windfall gain to the pharmaceuticals companies at the cost of endangering lives of million of Indians.

Advocate M L Sharma, who filed the petition and mentioned the case for urgent hearing, submitted that allowing pharmaceuticals companies to raise price as per their choice to secure wind fall gain involves serious corruption and also a life threat to the common general public.

“There are around 4.1 crore diabetes, 5.7 crore coronary heart disease, 22 lakh TB, 11 lakh cancer, 25 lakhHIV/AIDS and 6 crores blood pressure patients in India which are facing life threat and another life threat due to impugned circular for decontrolling order and price rise in medicines,” the petition said.

Drug pricing regulator NPPA had withdrawn guidelines for price control issued under Para 19 of the Drug Prices Control Order (DPCO), 2013.

The National Pharmaceutical Pricing Authority (NPPA) had invoked Para 19 of the Drug Prices Control Order (DPCO) to cap prices of 108 cardiac and diabetes drugs on July 10.

The drug regulator, in an earlier notification, had invoked Paragraph 19 of DPCO, 2013 to bring 108 anti-diabetic and cardiovascular formulation packs under the price control.

Under the Drug Price Control Order (DPCO) 2013, the Government already controls the prices of 348 drugs listed in the National List of Essential Medicines (NLEM).

By invoking para 19 of DPCO, NPPA had extended price control to drugs outside of NLEM. PTI

The Pharma Times News Bureau

Recent Posts

New medical nutrition ingredient combines high-protein with “best taste yet”

New Delhi, November 06, 2024: Arla Foods Ingredients has launched a new whey protein hydrolysate…

18 hours ago

6 Early Signs of Ovarian Cancer

By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…

18 hours ago

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

2 days ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

3 days ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

5 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

6 days ago